Chat
Recent Searches
Part of Thermo Fisher Scientific  
 
 
 
Open Biosystems’ Open Access RNAi Program adopted by John’s Hopkins University and University of Manitoba
Unique program makes genome scale analysis affordable and accessible to all researchers

HUNTSVILLE, Ala.—April 23, 2007—Open Biosystems, Inc., focused on the commercialization of leading-edge life science research tools for drug discovery, announced today that leading research institutions across North America continue to adopt its Open Access RNAi Program. Johns Hopkins University and University of Manitoba have recently purchased access to Open Biosystems shRNAmir and shRNA technologies for RNAi by joining the Open Access RNAi Program.

Participation in the Open Access Programs allows all research laboratories within an institution access to its choice of Open Biosystems’ portfolio of genome-wide resources including RNAi. The Open Access Program, unique in this field, supports Open Biosystems’ vision of supporting basic and medical research and reinforces its commitment to expanding access to research reagents for the life sciences community.

“Open Biosystems’ Open Access Programs for RNAi and genomic resources provides a unique consolidated toolkit for murine and human gene analysis to our faculty members for defining the function, distribution and therapeutic potentials of human gene products in health and disease said Sam Kung, Assistant Professor, Department of Immunology. Under the support of the Dean Strategic Research Fund, we have established the Biomedical Functionality Resource at the Faculty of Medicine, University of Manitoba to promote university-wide gene discovery and validation in multiple human diseases”

“The Open Access Programs from Open Biosystems were created to address the key needs of our academic customers. Allowing institution-wide sharing of genome-scale resources in an organized and technically supported manner continues our commitment to facilitate genome-scale analysis at the bench top of individual scientists” said Troy Moore, Chief Technical Officer of Open Biosystems.

Open Biosystems’ portfolio of RNAi resources include shRNAmir lentiviral and retroviral libraries targeting the entire human and mouse genomes, the RNAi Consortium human and mouse lentiviral shRNA libraries as well as RNAi collections targeting Drosophila, C. elegans and Zebrafish. These leading edge RNAi resources facilitate gene analysis on a genome scale. Participation in the Open Access RNAi program, provides researchers the most complete and flexible access to rapidly evolving RNAi technologies.

About Open Access RNAi
The Open Biosystems Open Access RNAi Program gives entire academic systems, including multiple campuses, access to the company’s advanced shRNA libraries, priority technical support, and continued access to all extensions of existing libraries as well as library upgrades. In this manner, Open Biosystems supports academic research without imposing heavy financial burdens on individual labs. The program is customizable and can be tailored to fit the diverse needs of research institutions worldwide. Complete details can be found at www.openbiosystems.com/OpenAccessRNAi

About Open Biosystems
Open Biosystems, Inc. develops, manufactures and markets genomic research tools to scientists and researchers in corporate, academic and government laboratories. These research tools provide investigators with standardized high-quality genes, RNAi and antibodies for interrogating gene function in relation to oncology, neuroscience and metabolic disorders. Founded in 2001, Open Biosystems is headquartered in Huntsville, Alabama. For more information and details for ordering, please visit www.openbiosystems.com.

Contacts:
Gwen D. Fewell, PhD
Open Biosystems Inc.
gfewell@openbiosystems.com